A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis

Knee Osteoarthritis Clinical Trial

Official title:

A Two-stage 6-month Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy Intra-articular Administration of JTA-004 in Patients With Symptomatic Knee Osteoarthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02740231
• Other study ID #: JTA-KOA1
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: February 2016
• Est. completion date: April 27, 2018

Study information

• Verified date: October 2021
• Source: Bone Therapeutics S.A
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Osteoarthritis (OA) is the most common joint disease affecting millions of people around the world, for which there is unfortunately no cure. Among existing therapies, viscosupplementation, i.e., the injection of hyaluronic acid into the joint, has an established place in the symptomatic treatment of knee OA. The present Phase IIb/III aiming to assess the safety and efficacy of JTA-004 is organized in two phases. With results obtained in the first phase the best dose of JTA-004 is determined, and the efficacy of the selected dose will then be confirmed in the second phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: April 27, 2018
• Est. primary completion date: April 27, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 79 Years

Eligibility

Inclusion Criteria:

• Ambulatory
• Diagnosed with primary knee osteoarthritis, fulfilling the following American College

of Rheumatology (ACR) criteria at the target knee:

• Pain = 40 mm on a 0-100 mm VAS during the 3 days preceding the date of the screening visit
• Morning stiffness not exceeding 30 minutes
• Kellgren-Lawrence grade II or III
• Insufficient / failed response to analgesic and / or NSAIDs
• No physical therapy of the knee, and knee braces for the entire duration of study
• Ability to provide a written, dated, and signed informed consent prior to any study related procedure, and to understand and comply with study requirements Exclusion Criteria:

Current symptoms and/or signs related to the disease under study:

• Isolated symptomatic femoropatellar OA of the target knee
• History of trauma or surgery or arthroscopy at the target knee within 6 months before inclusion
• Concomitant inflammatory disease or other condition affecting the joints (e.g., rheumatoid arthritis, septic arthritis, inflammatory joint disease, metabolic bone disease, psoriasis, gout, microcrystalline arthropathies/chondrocalcinosis, Paget's disease)
• Any musculoskeletal condition (such as hip osteoarthritis, amputation, neurologic disorder) that would impede measurement of efficacy at target knee
• Target knee prosthesis planned within 12 months after the Screening Visit

Current or previous diagnoses, signs and/or symptoms:

• Uncontrolled diabetes mellitus, end-stage hepatic or renal disease
• Current (or within the last 5 years prior to entering the study) history of solid or haematological neoplasia or bone marrow transplantation (except for basal cell carcinoma and completely excised squamous cell carcinoma)
• Other severe acute or chronic medical or psychiatric conditions or pre-dispositions or laboratory abnormalities, as judged by the Investigator
• Current or past history of coagulation disorders, as judged by the Investigator
• Hypersensitivity to any components of HA-based injection products
• History of hypersensitivity to human biological material including blood and blood derived products, potential excipients and residues from manufacturing process documented clinically or by laboratory tests
• Hypersensitivity to avian proteins
• Life expectancy less than 6 months

Current or previous treatment:

• Participation in another clinical study within 6 months prior to Screening
• Patients previously treated with JTA-004
• Treatment:
• Within 6 months prior to Screening: intra-articular hyaluronic acid injection at the target knee
• Within 2 months prior to Screening: intra-articular glucocorticoids at the target knee
• Current chemo-, radio- or immuno-cancer-therapy or immunosuppressive therapy
• Current anti-hypertensive medication the effects of which are known to be potentiated by a single dose of clonidine
• Current (or within 6 months prior to Screening) illicit drug abuse

Safety aspects concerning female subjects of childbearing potential:

• Females who are pregnant, lactating or woman with childbearing potential (last menstrual bleeding less than 12 months ago) unwilling to use medically acceptable contraception, or women with childbearing potential unwilling to perform a pregnancy test before administration of study treatment.

Other exclusion criteria:

• Body Mass Index (BMI) of 35 kg/m2 or greater

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• JTA-004 intra-articular injection
Each patient will undergo a single injection of JTA-004 into the knee joint

Device:
• Reference product intra-articular injection
Each patient will undergo a single injection of Reference product into the knee joint

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bone Therapeutics S.A

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6	The primary endpoint is the Western Ontario McMaster universities (WOMAC®) VA3.1 Pain Subscale (subscale A): the individual changes in WOMAC® VA3.1 Pain Subscale Score between Baseline and Month 6 were calculated and compared by analysis of covariance (ANCOVA), adjusted for baseline value, to the Reference group.; Results are expressed as "adjusted mean" based on the model used for group comparison.; WOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The WOMAC® Index Pain Subscale (VAS format) was used. The VAS score was determined by measuring in millimetres from the left-hand end of the line to the point that the patient marks (0-100 mm) for 5 questions. Results are summed and normalized on a 100 mm scale: 0 represents no knee pain and 100 extreme knee pain.	Baseline and 6 months
Secondary	WOMAC® Pain Subscale at Month 3	The primary endpoint is the Western Ontario McMaster universities (WOMAC®) VA3.1 Pain Subscale (subscale A): the individual changes in WOMAC® VA3.1 Pain Subscale Score between Baseline and Month 3 were calculated and compared by analysis of covariance (ANCOVA), adjusted for baseline value, to the Reference group.; Results are expressed as "adjusted mean" based on the model used for group comparison.; WOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The WOMAC® Index Pain Subscale (VAS format) was used. The VAS score was determined by measuring in millimetres from the left-hand end of the line to the point that the patient marks (0-100 mm) for 5 questions. Results are summed and normalized on a 100 mm scale: 0 represents no knee pain and 100 extreme knee pain.	Baseline and 3 months
Secondary	WOMAC® Total Score Over Time	The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and 2 weeks were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.; Results are expressed as "adjusted mean" based on the model used for group comparison.; WOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity and osteonecrosis symptoms. The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of k	Baseline and 2 weeks
Secondary	WOMAC® Total Score Over Time	The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and Month 3 were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.; Results are expressed as "adjusted mean" based on the model used for group comparison.; WOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms. The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of knee disease severity.	Baseline and 3 months
Secondary	WOMAC® Total Score Over Time	The Western Ontario McMaster universities (WOMAC®) VA3.1 Total Score was used: the individual changes in WOMAC VA3.1 Total Score between Baseline and Month 6 were calculated and compared by Mixed-Effect Model for Repeated Measurements, adjusted for baseline value, to the Reference group.; Results are expressed as "adjusted mean" based on the model used for group comparison.; WOMAC Osteoarthritis Index is a tri-dimensional, self-administered, patient-centred health status questionnaire for knee disease severity ans osteonecrosis symptoms.The Total score (VAS format) was determined by measuring in millimetres from the left hand end of the line to the point that the patient marks (0-100 mm) for the pain (5 questions), stiffness (2 questions), and physical function (17 questions). Results are normalized on a 0-100 mm scale format. A higher score represents a higher degree of knee disease severity.	Baseline and 6 months